Morgan Stanley Begins Coverage on Hinge Health (NYSE:HNGE)

Stock analysts at Morgan Stanley assumed coverage on shares of Hinge Health (NYSE:HNGE) in a research note issued on Monday, MarketBeat reports. The brokerage set an “overweight” rating and a $46.00 price target on the stock. Morgan Stanley’s price objective points to a potential upside of 22.44% from the stock’s previous close.

HNGE has been the topic of several other research reports. Needham & Company LLC initiated coverage on shares of Hinge Health in a research report on Monday. They set a “buy” rating and a $47.00 price objective on the stock. Evercore ISI started coverage on shares of Hinge Health in a research note on Monday. They set an “outperform” rating and a $50.00 price target on the stock. Canaccord Genuity Group started coverage on shares of Hinge Health in a research note on Monday. They issued a “buy” rating and a $52.00 price objective for the company. KeyCorp started coverage on shares of Hinge Health in a report on Monday. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Bank of America initiated coverage on Hinge Health in a report on Monday. They set a “buy” rating and a $42.00 target price on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and a consensus target price of $46.00.

Hinge Health Stock Up 3.8%

HNGE opened at $37.57 on Monday. Hinge Health has a fifty-two week low of $33.42 and a fifty-two week high of $43.80.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.